Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therapeutics reported Q3 results and provided pipeline updates, highlighting progress in Alzheimer’s programs and its NeuroShuttle nonviral delivery platform, and the company remains on track for key milestones in 2026, including PET imaging data for VY7523 and an IND filing for siRNA therapy VY1706, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)
- Voyager Therapeutics expects cash to fund operations into 2028
- Voyager Therapeutics, Transition Bio entered into drug discovery collab
- Voyager Therapeutics Advances Alzheimer’s Study with VY7523
- Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating